<DOC>
	<DOCNO>NCT00615810</DOCNO>
	<brief_summary>This study aim investigate whether patient switch backbone Kivexa Truvada , already raise total cholesterol prior switch , improvement total cholesterol 12 week treatment . If improvement demonstrate study aim show whether beneficial effect patient 's overall cardiovascular risk long term prognosis .</brief_summary>
	<brief_title>ROCKET I - Randomized Open Label Switch Cholesterol Elevation Kivexa Evaluation Trial</brief_title>
	<detailed_description>This protocol Phase 4 , open label , randomize , UK multi-center , control study ass effect lipid profile switch stable HAART regimen Kivexa + EFV daily Atripla adult HIV 1 infected subject raise cholesterol . At Baseline , subject randomize 1:1 one two treatment group : Treatment Group 1 : switch Atripla Treatment Group 2 : Continuation previous stable HAART regimen Kivexa + EFV Initiation treatment study drug must take place within 24 hour Baseline visit . At Week 12 , subject Treatment Group 2 ( continuation Kivexa EFV regimen ) switch Atripla . Treatment group continue Week 24</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Equal great 18 year old Plasma HIV RNA le 50 copies/mL equal great 12 week prior Screening Stable HAART regimen Kivexa + EFV equal great 24 week prior Screening Documented confirm raise total cholesterol great equal 5.2 mmol/L last two consecutive test ( least 4 week apart ) last result less equal 4 week prior Screening Subject willing continue current unmodified HAART 12 week randomize Group 2 Subjects require concomitant lipid regulate therapy must establish stable dose/frequency great equal 12 week prior Screening expect remain stable dose frequency throughout treatment phase study Adequate renal function calculate creatinine clearance great equal 60 mL/min accord Cockcroft Gault formula Negative serum pregnancy test ( female childbearing potential i.e. , surgically sterile least 2 year postmenopausal ) Hepatic Total Bilirubin ≤ 1.5 mg/dL Adequate haematologic function absolute neutrophil count ≥ 1000/mm3 , platelet ≥ 25,000/mm3 , Haemoglobin ≥ 8.0g/dL Women childbearing potential ( WOCBP ) must use two method contraception avoid pregnancy throughout study 12 week last dose study drug manner risk pregnancy minimize . Subjects may choose two ( barrier plus highly effective method see section 7.8 discussion ) birth control method list : Hormonal birth control drug Male female condom without spermicidal gel Diaphragm cervical cap without spermicidal gel Intrauterine device Female subject utilize hormone contraceptive one birth control method must use method least 3 month prior study dose Female subject postmenopausal less 2 year require FSH great equal 40 mIU/mL . If FSH le 40 mIU/mL , subject must agree use highly effective method birth control ( describe ) participate study Male subject sexually active must willing use effective barrier contraception ( e.g . condom spermicide ) heterosexual intercourse screen completion study continue 12 week last dose study drug Life expectancy great equal 1 year The ability understand sign write informed consent form , must obtain prior initiation study procedure Pregnant lactate subject Previous treatment emtricitabine ( FTC ) , tenofovir DF ( TDF ) adefovir dipivoxil ( ADV ) Known hypersensitivity emtricitabine ( FTC ) , tenofovir DF ( TDF ) , efavirenz ( EFV ) Truvada Documented resistance study drug ( either genotypic phenotypic ) Severe hepatic impairment Hepatic transaminase ( AST ALT ) great equal 5 time upper limit normal ( ULN ) Subjects receive ongoing therapy medication contraindicate study drug . Administration medication must discontinue least 30 day prior Baseline visit duration study period . The full list disallow medication find appendix 7 . Active , serious infection ( HIV infection ) require parenteral antibiotic therapy within 15 day prior screen Prior history significant renal bone disease Any current know clinical symptomatic laboratory parameter GSI grade 4 . Asymptomatic grade 4 abnormality permit discretion Investigator deem clinically appropriate ( exclude AEs laboratory parameter mention elsewhere inclusion/exclusion criterion ) . Abnormalities deem insignificant Investigator must discuss Sponsor prior enrollment . Malignancy cutaneous Kaposi sarcoma ( KS ) basal cell carcinoma . Subjects biopsyconfirmed cutaneous KS eligible , must receive systemic therapy KS within 30 day baseline anticipate require systemic therapy study Current alcohol substance use judge investigator potentially interfere subject study compliance Subjects currently take part clinical trial use investigational product , exception study treatment study stop 1 month Any clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>LDL</keyword>
	<keyword>HDL</keyword>
	<keyword>triglyceride</keyword>
	<keyword>non HDL cholesterol</keyword>
	<keyword>cholesterol</keyword>
	<keyword>HIV 1</keyword>
	<keyword>Metabolic parameter</keyword>
	<keyword>treatment experience</keyword>
</DOC>